Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells

Docetaxel has been the standard first-line therapy in metastatic castration resistant prostate cancer. The survival benefit is, however, limited by either primary or acquired resistance. In this study, Du145 prostate cancer cells were converted to docetaxel-resistant cells Du145-R and Du145-RB by in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Springerplus
Egile Nagusiak: Ma, Yuanjun, Miao, Yali, Peng, Zhuochun, Sandgren, Johanna, De Ståhl, Teresita Díaz, Huss, Mikael, Lennartsson, Lena, Liu, Yanling, Nistér, Monica, Nilsson, Sten, Li, Chunde
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer International Publishing 2016
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5078122/
https://ncbi.nlm.nih.gov/pubmed/27822437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-016-3543-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak